SCHEMBL20836948

SCHEMBL20836948

COc1cccc2oc(-c3c(C(=O)O)[nH]c4c(-c5ccccc5)c(C#N)nn4c3=O)nc12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNKS O95271 1/20 0.35
▸ TNKS2 Q9H2K2 1/20 0.35
▸ PARP2 Q9UGN5 1/20 0.35
▸ DHODH Q02127 1/20 0.35
▸ F2RL3 Q96RI0 2/20 0.35
▸ HTT P42858 2/20 0.35
▸ PDE10A Q9Y233 1/20 0.34
▸ TOP2A P11388 1/20 0.34
▸ MAT2A P31153 1/20 0.34
▸ HPSE Q9Y251 1/20 0.33
▸ ADORA2A P29274 2/20 0.32
▸ HPGD P15428 3/20 0.32
▸ MEN1 O00255 2/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ HSD17B10 Q99714 2/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ ESR2 Q92731 1/20 0.32
▸ KDM4E B2RXH2 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20914077 0.89 TNKS (0.37) TNKSTNKS2PARP2F2RL3HTT
SCHEMBL20914031 0.86 APLNR (0.35) TNKSTNKS2PARP2F2RL3HTT
SCHEMBL20914160 0.86 TNKS (0.35) TNKSTNKS2PARP2F2RL3HTT
SCHEMBL20819040 0.85 TNKS (0.35) TNKSTNKS2PARP2DHODHF2RL3
SCHEMBL20819060 0.84 APLNR (0.35) TNKSTNKS2PARP2F2RL3HTT
SCHEMBL20914298 0.83 APLNR (0.39) TNKSTNKS2PARP2F2RL3HTT
SCHEMBL20837249 0.81 TNKS (0.37) TNKSTNKS2PARP2DHODHF2RL3
SCHEMBL20913913 0.81 KCNA5 (0.38) TNKSTNKS2PARP2F2RL3HPSE
SCHEMBL20914255 0.80 TNKS (0.37) TNKSTNKS2PARP2DHODHF2RL3
SCHEMBL20913994 0.80 POLB (0.37) TNKSTNKS2PARP2DHODHF2RL3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
WO-2019055750-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF Aduro Biotech, Inc. (US) 2019-03-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 TNKS 531/4885TNKS2 932/4885PARP2 1671/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 TNKS 531/4885TNKS2 932/4885PARP2 1671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback